<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lee SY</submitter><funding>This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government</funding><funding>This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT)</funding><funding>the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education</funding><pagination>4</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12779986</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(1)</volume><pubmed_abstract>This study aimed to introduce a synergistic integration platform based on single-cell and proteotranscriptomics for drug repositioning (SIMD) to repurpose breast cancer drug candidates by considering the bidirectional nature of molecular dynamics in protein transcriptomics and tumor heterogeneity at the single-cell level. SMID consists of two core methods: the anti-correlated proteotranscriptome perturbation score (ACPS), which measures the negative correlation between perturbagen-induced expression signatures and multi-omic expression profiles from patient-derived breast cancer samples; and perturbagen repositioning scoring and scRNA-seq data (PPNE), which ranks perturbagens exhibiting high ACPS scores and inverse transcriptomic associations with neoplastic epithelial (NE) cells identifie</pubmed_abstract><journal>NPJ breast cancer</journal><pubmed_title>SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning.</pubmed_title><pmcid>PMC12779986</pmcid><funding_grant_id>RS-2023-NR077274</funding_grant_id><funding_grant_id>2021R1I1A1A01058604</funding_grant_id><pubmed_authors>Lee YR</pubmed_authors><pubmed_authors>Lee SY</pubmed_authors><pubmed_authors>An JH</pubmed_authors><pubmed_authors>Song MY</pubmed_authors></additional><is_claimable>false</is_claimable><name>SIMD: Synergistic integration mutualistic platform based on single-cell and proteotranscriptomics for drug repositioning.</name><description>This study aimed to introduce a synergistic integration platform based on single-cell and proteotranscriptomics for drug repositioning (SIMD) to repurpose breast cancer drug candidates by considering the bidirectional nature of molecular dynamics in protein transcriptomics and tumor heterogeneity at the single-cell level. SMID consists of two core methods: the anti-correlated proteotranscriptome perturbation score (ACPS), which measures the negative correlation between perturbagen-induced expression signatures and multi-omic expression profiles from patient-derived breast cancer samples; and perturbagen repositioning scoring and scRNA-seq data (PPNE), which ranks perturbagens exhibiting high ACPS scores and inverse transcriptomic associations with neoplastic epithelial (NE) cells identifie</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T11:22:21.77Z</modification><creation>2026-05-29T03:12:31.809Z</creation></dates><accession>S-EPMC12779986</accession><cross_references><pubmed>41444222</pubmed><doi>10.1038/s41523-025-00869-x</doi></cross_references></HashMap>